Abstract
Introduction
Systemic lupus erythematosus (SLE) is a progressive, systemic autoimmune disease with multi-organ engagement, characterized by an immune response directed against selfantigens [1] . The SLE target tissues include skin, kidneys, joints, and the central nervous system [1] . Exposure to certain chemicals, drugs, food, and infectious factors also contributes to SLE incidence [2, 3] . Moreover, there is an evident genetic background in the incidence of this autoimmune disorder [4] [5] [6] .
Three major processes are considered in the initiation, development, and clinical manifestation of SLE; they include an increase in the plasma concentration of nuclear auto-antigens, T-cell-dependent stimulation of B cells for the biosynthesis of antinuclear antibodies (Ab), and organ damage mediated by anti-double stranded DNA Ab and immune complexes [7] [8] [9] .
Increased apoptosis and reduced removal of apoptotic cells lead to the formation of necrotic cells, which are source of nuclear antigens for biosynthesis of Ab [10, 11] . Cytotoxic T lymphocytes involved in killing other host cells may be signiWcant producers of preferential and selective autoantigens [12] . T cells from lupus patients may kill autologous monocytes/macrophages, and may thus contribute to both increase of the amount of antigenic apoptotic material and the reduction of its clearance [13, 14] .
It has been concluded that defective helper functions of CD4 + T cells can contribute to improper activation of B cells and autoantibody production [15] [16] [17] [18] . Despite CD4 + T cells function mainly as helper cells, a, subpopulation of these cells also functions in an eVector capacity by carrying out cytotoxicity in a peptide-speciWc and MHC class II-restricted mode [19] . The latter function of CD4 + T cells mainly depends on granzyme B and perforin-1 (PRF1) exocytosis rather than on CD95-ligand binding to CD95 [19] . An increased presence of cytotoxic CD4 + T cells has been associated with vascular damage and incidence of various autoimmune diseases, including SLE [20] [21] [22] [23] [24] . The overexpression of PRF1 both in CD4 + T and in CD8 + T cells from peripheral mononuclear cells (PBMC), and its role in SLE pathogenesis has been demonstrated [24, 25] . Kaplan et al. [24] , employing staining of PBMC and Xow cytometry analysis, showed a signiWcant correlation between percentage of PRF1 + CD4 + T cells in PBMC and disease activity in SLE patients.
We decided to examine mRNA and protein levels in whole CD4
+ T cells from a larger group of SLE patients (n = 41) and healthy individuals (n = 34) than those demonstrated by Kaplan et al. [24] . Whole CD4 + T cells from whole peripheral blood were isolated by positive biomagnetic separation. Isolated mRNA and proteins from CD4 + T cells were used for reverse transcription, real-time quantitative PCR, and Western blotting analysis. Subsequently, we determined whether there exist correlations between increased PRF1 transcript and protein levels in CD4 + T cells and SLE disease activity.
Materials and methods

Patients and controls
As much as 41 [26, 27] . Disease activity for the SLE patients was assessed using the SLEDAI scale (Table 1 ) [28] . Twenty-four patients were treated by prednisone. Seventeen patients were receiving methyloprednisone, and ten patients were also receiving hydroxychloroquine. To reduce the eVect of corticosteroid medication on our results, patients who were on prednisone or methyloprednisone were asked not to take this medication for at least 24 h before drawing blood. Clinical manifestations of SLE in the patient group included central nervous system (22%), vascular (20%), renal (42%), musculoskeletal (29%), serosal (20%), dermal (34%), immunologic (85%), febrile (8%), and hematologic (29%) components.
Both patients and control groups were of Polish Caucasian origin. The control group included 34 healthy individuals (32 women and 2 men). The mean age of healthy individuals was 36.6 § 9.6 years. The protocol of the investigation was approved by the Local Ethical Committee of Poznaj University of Medical Sciences. Written informed consent was signed by all participating individuals.
Antibodies
Rabbit polyclonal anti-PRF1 Ab (H-315), goat anti-rabbit horseradish peroxidase (HRP)-conjugated Ab, and antiactin HRP-conjugated Ab (clone I-19) were provided by Santa Cruz Biotechnology (Santa Cruz, CA).
CD4 + T-cell isolation
The CD4 + cells were isolated from a 10 ml whole peripheral blood sample taken from each patient, employing the positive biomagnetic separation technique using DETACHaBEADs ® M-450 CD4 from Dynal Biotech (Lake Success, NY) (29) . The Xow cytometry analysis (n = 29) indicated 95.6 § 1.4% purity of CD4 + T cells.
Real-time quantitative PCR (RQ-PCR) analysis of PRF1 transcript levels in CD4 + T cells
Total RNA was isolated according to the method of Chomczyjski and Sacchi [29] . RNA samples were treated with DNase I, and 1 g RNA was reverse-transcribed into cDNA using oligo-dT primers. RQ-PCR was conducted in a Light Cycler real-time PCR detection system from Roche Diagnostics GmbH, (Mannheim, Germany) using SYBR ® Green I as detection dye. Target cDNA was quantiWed using relative quantiWcation method with a calibrator. The calibrator was prepared as a cDNA mix from all SLE and control samples and consecutive dilutions were used to create a standard curve as described in Relative QuantiWcation Manual Roche Diagnostics GmbH, (Mannheim, Germany). For ampliWcation, 2 l of cDNA solution was added to 18 l of QuantiTect ® SYBER ® Green PCR Master Mix QIAGEN GmbH (Hilden, Germany) and primers. The quantity of PRF1 transcript in each sample was standardized by human mitochondrial ribosomal protein L19 (hMRPL19). The PRF1 cDNA 170 bp amplicon was ampliWed employing the pair of primers 5ЈCACCCTCTGTGAAAA TGCCCTAC3Ј (forward) and 5ЈTCCAGTCGTTGCGGAT GCTAC3Ј (reverse).
The hMRPL19 cDNA 171 bp amplicon was ampliWed using primers 5ЈACTTTATAATCCTCGGGTC 3Ј (forward) and 5ЈACTTTCAGCTCATTAACAG 3Ј (reverse).
These PRF1 and hMRPL19 primers were designed based on sequences ENST00000373209 and ENST00000393909, respectively, located in Ensembl Genome Browser (http:// www.ensembl.org). The PRF1mRNA levels were expressed as multiples of these cDNA concentrations in the calibrator.
Western blot analysis of PRF1 protein contents in CD4 + T cells
CD4
+ lymphocytes were lysed in lysis buVer, and 10 g of protein was resuspended in sample buVer. The proteins were separated on 10% Tris-glycine gel using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membrane. Immunodetection was performed with rabbit polyclonal anti-PRF1, and HRPconjugated goat anti-rabbit Ab. The membranes were reblotted with anti-actin HRP-conjugated Ab to equalize protein loading of the lanes. To detect the examined protein from the same blot membrane we used stripping buVer. Bands were revealed using SuperSignal West Femto Maximum Sensitivity Substrate Pierce (Rockford, IL). The quantities of Western blot-detected PRF1 and -actin proteins were determined based on the band optical density. The band densitometry readings were normalized to -actin loading control to calculate the PRF1 to -actin optical density ratio.
Statistical analysis
Statistical analysis was conducted using StatSoft, Inc. (2001) . STATISTICA (data analysis software system), version 6 http://www.statsoft.com. The signiWcance of diVerences between groups was determined using nonparametric Mann-Whitney test. Correlations between PRF1 expression and disease activity as deWned by the SLEDAI scale were assessed by Spearman analysis.
Results
PRF1 transcript and protein levels in CD4 + T cells from SLE patients and controls
To compare PRF1 transcript and protein levels in CD4 + T cells from SLE patients and controls, we used RQ-PCR and Western blotting analysis, respectively. There was no signiWcant increase in PRF1 transcript level in SLE CD4 + T cells as compared to controls (p = 0.908) (Fig. 1a, Table 2 ). However, we observed signiWcantly higher content of PRF1 protein in CD4 + T cells from SLE patients as compared to + T cells were isolated from peripheral blood by positive biomagnetic separation technique, and were immediately used for RNA and protein isolation. Total RNA was reverse-transcribed, and cDNAs were investigated by RQ-PCR relative quantiWcation analysis. The PRF1 mRNA levels were corrected to the amount of hMRLP19 transcript. The amounts of PRF1 mRNA were expressed as the natural logarithm of multiples of these cDNA copies in the calibrator. Proteins were separated using SDS-PAGE, transferred, and the membranes were immunoblotted, respectively, with primary anti-PRF1 Ab and secondary Ab. The membranes were reblotted with anti--actin HRP-conjugated Ab. The amount of Western blot-detected PRF1 proteins was presented as the natural logarithm of PRF1 to -actin band optical density ratio. (Open circle) and (Wlled circle) represent transcript and protein levels in controls and SLE patients, respectively. *Median (range), ND non detected (Fig. 1b, c , Table 2 ). There was no correlation between PRF1 transcript and protein levels in SLE CD4 + T cells and disease activity deWned by the SLEDAI scale (Fig. 2a, b) . Also we did not Wnd a relationship between patients' age, disease duration, drug treatment, and type of individual organ manifestation with PRF1 transcript and protein levels in SLE CD4 + T cells (data not shown). Fig. 2 The correlation between PRF1 transcript (a) and protein (b) in CD4 + T cells and clinical activity of SLE scored in the SLEDAI scale. The CD4 + T cells were used for RNA and protein isolation. Total RNA was reverse-transcribed into cDNAs and investigated by RQ-PCR relative quantiWcation analysis. PRF1 mRNA levels were corrected to hMRLP19 transcript levels. The quantities of PRF1 mRNA were expressed as the natural logarithm of multiples of these cDNA copies in the calibrator. The CD4 + T-cell proteins were separated using SDS-PAGE, transferred, and the membranes were immunoblotted, respectively, with primary anti-PRF1 Ab and secondary Ab. The membranes were reblotted with anti--actin HRP-conjugated Ab. The amount of Western blot-detected PRF1 was presented as the natural logarithm of PRF1 to -actin band optical densities ratio. r Spearman correlation coeYcient 
A B
Discussion
It has previously been demonstrated that there is an increased expression of many proteins responsible for defective function of CD4 + T cells [15, 16, 18] . These proteins include signal molecules, transcription factors, components of TCR/CD3 complex, costimulatory proteins, cytokines, and molecules involved in the cytotoxic response [15, 16, 18] .
PRF1 protein, with molecular mass of 60 to 75 kD, is a pore-forming molecule presented in cytotoxic lymphocytes, which execute immune-mediated cell lysis [30] . The PRF1 gene is expressed primarily in NK cells and eVector CD8 + T cells [31, 32] . PRF1 is also expressed in a subpopulation of cytotoxic CD4 + T cells, which may combat various pathogens [33] [34] [35] [36] [37] [38] [39] . An increased number of cytotoxic CD4 + T cells has been observed in patients with multiple sclerosis, rheumatoid arthritis, inXammatory bowel disease, and acute coronary syndromes [20] [21] [22] [23] .
Lu et al. [40] demonstrated that DNA methylation and chromatin structure regulate PRF1 expression in T cells. Moreover, Kaplan et al. [24] showed that DNA methylation inhibitors increased PRF1 expression in CD4 + T cells. This increase in PRF1 transcription in CD4 + T cells was due to demethylation of a DNA region, which is hypomethylated in primary CD8 + T cells expressing PRF1. Kaplan et al. [24] also indicated that increased PRF1 transcription in CD4 + T cells from SLE patients was related to demethylation of this DNA region [24] . Recently, Luo et al. [41] disclosed that DNA demethylation at the PRF1 locus is responsible for PRF1 overexpression in CD4 + T cells from patients with subacute cutaneous lupus erythematosus.
We observed signiWcantly higher levels of PRF1 protein in SLE CD4 + T cells than in healthy individuals. Our Wndings are consistent with Kaplan et al. [24] , who demonstrated a signiWcant increase in PRF1 protein levels in SLE patients. They also indicated that aberrant PRF1 protein levels in SLE CD4 + T cells may contribute to killing of autologous monocytes [24] .
We also found higher PRF1 transcript levels in SLE CD4 + T cells than in controls, but this diVerence was not statistically signiWcant and did not correlate with disease activity. Although PRF1 protein level was higher in SLE CD4 + T cells than in controls, it also did not correlate with disease activity. Our Wndings suggest that an increased PRF1 protein content in SLE CD4 + T cells does not perpetuate disease activity in our investigated group.
Kaplan et al. [24] observed that CD4 + T cells from patients with active, but not inactive, lupus exhibited increased PRF1 transcript levels in CD4 + T cells. Using Xow cytometry analysis, they also demonstrated that the increase in PRF1 protein contents in SLE CD4 + T cells was correlated to disease activity expressed by the SLEDAI scale [29] . These discrepancies between our observations and those of Kaplan et al. may result from the application of diVerent methods in the determination of PRF1 protein levels in CD4 + T cells to establish correlation with disease activity.
The cytotoxic/eVector CD4 + T cells make up a small amount of the whole circulating CD4 + T population [42] . These cells constitute the subset of CD45R0 + CD27 ¡ activated CD4 + T cells, which are formed during diVerentiation of naive CD45RA + CCR7 + T cells [42, 43] . Therefore, our analysis, conducted on the whole CD4 + T-cell population after immune magnetic enrichment, may underestimate PRF1 transcript and protein levels in cytotoxic/eVector CD4 + T cells. This may be responsible for the discrepancies observed between our results and those of Kaplan et al. [24] . These diVerences can also be due to varied genetic factors associated with the distinct racial structure of the examined groups or/and an exposure to disparate environmental factors contributing to SLE in these populations [3, 4] .
Our study conWrmed previous observations that demonstrated increased PRF1 protein contents in CD4 + T cells from SLE patients. However, we did not Wnd a correlation between PRF1 protein and transcript levels in CD4 + T cells and SLE disease activity. Therefore, our results require veriWcation in groups of SLE patients in other cohorts.
